Hsien-Shu Tsai Buys Shares of Apollomics, Inc.

Insider Hsien-Shu Tsai purchased 500 shares of Apollomics, Inc. on June 15, 2026.

Written by EarningsIQ · Published Jun 17, 2026, 2:01 AM EDT · Updated Jun 17, 2026, 5:00 AM EDT

Key Points

Hsien-Shu Tsai bought 500 shares of Apollomics, Inc. on June 15, 2026, with the stock trading near $13.85.
Apollomics, Inc. is a biopharmaceutical company with a market cap of approximately $31.8 million.
Insider activity includes multiple transactions on June 15, 2026, with both buys and sells reported.

Hsien-Shu Tsai recently bought 500 shares of Apollomics, Inc. (NasdaqCM: APLM) on June 15, 2026. The transaction did not involve a planned purchase, and the shares were acquired at no cost. Apollomics shares are currently trading around $13.85.

Insider Buying and Selling at Apollomics, Inc.

On June 15, 2026, several insiders engaged in transactions involving Apollomics stock. Chen Hung-Wen, the Chief Executive Officer, bought 5,000 shares, while Chen Hong-Jung and Chu Yi-An each purchased 500 shares. On the selling side, Tsai Hsien-Shu sold 500 shares, and Chen Yi-Kuei, the Chief Operating Officer, sold 5,000 shares. These transactions were not part of any prearranged trading plans.

Apollomics, Inc. Stock Snapshot

Shares of Apollomics, Inc. (NasdaqCM: APLM) are trading near $13.85. The company's market capitalization stands at about $31.8 million. Apollomics is not currently profitable, reflected in its negative forward P/E ratio of -22.29. The stock has a beta of 1.526, indicating higher volatility compared to the broader market. Over the past 52 weeks, the stock has traded between $3.66 and $42.12, with a 50-day moving average of $14.25 and a 200-day moving average of $16.91. The company's current ratio is 0.957, and its quick ratio is 0.911.

Analysts Set New Price Targets

Analysts have been active in evaluating Apollomics. On May 8, 2024, H.C. Wainwright reiterated a 'buy' rating with a $2.00 price target. Earlier, on April 1, 2024, the firm maintained its 'buy' rating, setting a target of $5.00. In late 2023, H.C. Wainwright reiterated and initiated 'buy' ratings with targets of $17.00 and $18.00, respectively. EF Hutton maintained a 'buy' rating with a $25.00 target on May 25, 2023. The consensus among analysts is a 'buy' rating, with a mean target price reflecting positive sentiment.

About Apollomics, Inc.

Apollomics, Inc. is a clinical-stage biopharmaceutical company based in Foster City, California. It focuses on developing cancer therapies that harness the immune system and target specific molecular pathways. The company's product portfolio includes Vebreltinib, a c-Met inhibitor in Phase 2 trials for lung cancer, and APL-102, a tyrosine kinase inhibitor in Phase 1 trials. Apollomics also develops immuno-oncology treatments, including APL-501 and APL-502, aimed at treating solid tumors. Founded in 2015, the company operates with a small team of 14 employees under the leadership of CEO Mr. Hung-Wen Chen.

Bottom Line

Apollomics, Inc. has seen significant insider activity with both purchases and sales on June 15, 2026. While insider trading can provide insights, it's important to remember these actions are reported after the fact and are just one piece of the investment puzzle. The company's focus on innovative cancer therapies and its volatile stock performance continue to draw attention from investors and analysts alike.